OTTOBOCK HUMAN MOBILITY acquired by DHCARE
Context
DHCare has entered into an agreement to acquire Ottobock's Human Mobility business, which specializes in manual and power wheelchairs, as well as pediatric mobility solutions. This transaction is part of Ottobock's strategy to refocus its resources on its core, high-growth businesses, including prosthetics, neuro-orthotics, and exoskeletons. The divested business generates approximately €80 million in annual revenue, employs around 270 staff members, and comprises the German Human Mobility companies, as well as veldink4Kids, a Dutch specialist in pediatric wheelchairs. For DHCare, this acquisition represents a major strategic milestone and its first since the group's reorganization under its new shareholder structure. The deal significantly expands DHCare's mobility solutions portfolio and strengthens its presence in several key European markets, particularly in the DACH region, where Human Mobility has a long-standing strong position. By combining their expertise, DHCare and Human Mobility aim to create a pan-European platform that can offer an expanded range of clinical solutions, technical services, and after-sales support to patients, healthcare professionals, and payers. The transaction is expected to be completed in the second half of 2026.
OTTOBOCK HUMAN MOBILITY, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Human Mobility is Ottobock's dedicated business unit for wheelchairs and mobility solutions. The company designs, manufactures, and markets a comprehensive range of equipment aimed at enhancing the independence and quality of life of individuals with permanent or temporary functional limitations. Its portfolio includes manual and power wheelchairs, specialized seating systems, rehabilitation strollers, and pediatric mobility solutions for children with complex needs. The company has particular expertise in high-end motorized wheelchairs and customized devices designed to address demanding clinical situations. Headquartered in Germany with complementary activities in the Netherlands through veldink4Kids, Human Mobility has a strong presence in German-speaking countries and a solid reputation among specialized healthcare professionals in rehabilitation, neurology, and orthopedics. Its business model is built on close collaboration with therapists, rehabilitation centers, specialized distributors, and reimbursement agencies to provide tailored solutions that meet the specific needs of users.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 06/2026 | CORDENPHARMA | AMBIOPHARM | UNITED STATES | Life Sciences | CordenPharma, backed by private equity firm Astorg, entered into an agreement to acquire AmbioPharm, a US-based CDMO specializing in complex peptide APIs with manufacturing sites in the United States and China |
| 06/2026 | BRIDGEPOINT | OBAGI MEDICAL | UNITED STATES | Life Sciences | Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets |
| 06/2026 | COLUMBUS VENTURE PARTNERS / MERIEUX EQUITY PARTNERS | ONA THERAPEUTICS | SPAIN | Life Sciences | The closing of this oversubscribed 86.6 million dollar Series B financing represents a structural capitalization event designed to transition Ona Therapeutics into a clinical-stage oncology platform and fund operations through its primary clinical data readouts |
| 06/2026 | 3I | LABORATOIRE NUTERGIA | FRANCE | Life Sciences | The acquisition of a 51% controlling interest in Laboratoire Nutergia by 3i presents a primary leveraged buyout transaction designed to transition a mature, founder-led enterprise into an institutionalized platform capable of capturing pan-European market share |
| 06/2026 | MOTION EQUITY PARTNERS | POLARIS | FRANCE | Life Sciences | Motion Equity Partners has acquired a majority stake in Polaris, a leading manufacturer of omega-3 concentrates, from Demea Agro, which had invested in the company three years ago. This transaction is part of a broader strategy to drive external growth and international expansion, with ambitious plans to establish a US-based industrial site and double in size within the next five years |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Life Sciences | Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation |
| 04/2026 | FINE FOODS & PHARMACEUTICALS | SOFAR | ITALY | Life Sciences | The group has finalized a binding agreement to acquire the total share capital of the target from Alfasigma S.p.A., a maneuver designed to fundamentally expand its specialized manufacturing capabilities |
| 04/2026 | VITREX MEDICAL GROUP | HERNIAMESH | ITALY | Life Sciences | Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology |
| 04/2026 | AMERICAN INDUSTRIAL PARTNERS AIP | AVANOS MEDICAL | UNITED STATES | Life Sciences | American Industrial Partners has finalized a definitive agreement to acquire Avanos Medical in an all-cash transaction, a maneuver designed to fundamentally reinforce the target's competitive positioning in the specialized medical technology arena |
| 04/2026 | REVENIO GROUP CORPORATION | VISIONIX INTERNATIONAL | FRANCE | Life Sciences | The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market |
REFERENCES
Revenue range: 50M - 100M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OTTOBOCK HUMAN MOBILITY by DHCARE are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Acquirer: dhcare